Comparative Pharmacology
Head-to-head clinical analysis: CITANEST versus GLYDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CITANEST versus GLYDO.
CITANEST vs GLYDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that blocks sodium channels in nerve cell membranes, inhibiting depolarization and propagation of action potentials, resulting in reversible loss of sensation.
GLYDO (lidocaine) is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses.
Local anesthesia: 2-4 mL of 1% or 2% solution without epinephrine, maximum 5 mg/kg (300 mg for adults). Intravenous regional anesthesia: 0.5% solution, 40-60 mL, maximum 300 mg. Epidural: 1.5% solution, 15-20 mL, maximum 300 mg. Subarachnoid: 5% solution with glucose, 80-100 mg. Maximum total dose: 600 mg with epinephrine, 400 mg without epinephrine.
For anesthesia: 1-5% solution, 0.5-5 mg/kg IV or 2.5-15 mg intrathecally; for antiarrhythmic: 1-1.5 mg/kg IV bolus then 1-4 mg/min infusion.
None Documented
None Documented
Terminal elimination half-life approximately 1.5-2 hours in adults; prolonged in hepatic impairment or neonates.
Terminal elimination half-life is approximately 1.5 to 2 hours in adults with normal hepatic and renal function. In neonates, half-life is prolonged (up to 3-4 hours) due to immature hepatic metabolism.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Metabolites are excreted renally. Biliary/fecal excretion is minimal.
Renal excretion of unchanged drug accounts for approximately 10% of the dose; the remainder is metabolized in the liver to inactive metabolites that are excreted renally. Fecal elimination is negligible (<2%).
Category C
Category C
Local Anesthetic (Amide)
Local Anesthetic (Amide)